TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03164746

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry sheet Therapeutic body wraps
Description: At the beginning of the session, the patient's consent to proceed was orally obtained, as no session was compulsory. The therapists checked behavioral manifestations of refusal. Then, the patient was first wrapped in Dry damp sheets (cold phase) and covered up with a rescue and a dry blanket. Afterward the body spontaneously warmed up (warm phase). The patient was then invited to freely express his feelings.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WET sheet Therapeutic body wraps
Description: At the beginning of the session, the patient's consent to proceed was orally obtained, as no session was compulsory. The therapists checked behavioral manifestations of refusal. Then, the patient was first wrapped in wet damp sheets (cold phase) and covered up with a rescue and a dry blanket. Afterward the body spontaneously warmed up (warm phase). The patient was then invited to freely express his feelings.
Study: NCT02719210

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High Volume Plasma Exchange

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic 3% saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mannitol

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Elective positive pressure ventilation
Study: NCT02556346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-3724
Description: Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-3724
Description: Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-3724
Description: Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-3724
Description: Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-3724
Description: Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
Study: NCT01836029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTX-2337
Description: TLR8 Agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Study: NCT04142138

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DASH
Description: DASH diet is based on low salt, high potassium components, and is comprised of mainly fruits and vegetables. During hospitalization we will collect laboratory data of blood and urine, and follow participants clinically by measuring blood pressure.
Study: NCT00577707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: One tablet daily of erlotinib pills (150 mg daily) for the first 21 days. After surgery, you will be asked to take adjuvant erlotinib 150 mg po daily x 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: pemetrexed 500 mg/m\^2 every 3 weeks for 4 cycles treatment) on the first day of each cycle of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: cisplatin 75 mg/m\^2 every 3 weeks for 4 cycles treatment) on the first day of each cycle of treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Study: NCT02193867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sebelipase Alfa
Description: Sebelipase alfa is a recombinant human lysosomal acid lipase. The investigational medicinal product is an enzyme replacement therapy intended for treatment of participants with LAL-D. Dosing occurred once weekly for up to 3 years.
Study: NCT01890356

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial electrical stimulation
Study: NCT04522960

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MEG+hdEEG+MRI
Description: We will perform several tests:~* Neuropsychological testing to evaluate evolution of cognition during our study.~* Lumbar puncture, blood sampling, saliva and urine collection to assess melatonin levels at several timepoints within these biological fluids.~* MEG+hdEEG and MRI (to project MEG information) ; LTM-EEG to detect epileptiform activity in patients and healthy controls

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MEG+hdEEG+MRI
Description: We will perform several tests:~* Neuropsychological testing to evaluate evolution of cognition during our study.~* Lumbar puncture, blood sampling, saliva and urine collection to assess melatonin levels at several timepoints within these biological fluids.~* MEG+hdEEG and MRI (to project MEG information) ; LTM-EEG to detect epileptiform activity in patients and healthy controls
Study: NCT01513473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Injected subcutaneously (under the skin) once daily. Dose individually adjusted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Injected subcutaneously (under the skin) once or twice daily. Dose individually adjusted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Injected subcutaneously (under the skin) as mealtime bolus insulin. Dose individually adjusted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Injected subcutaneously (under the skin) as mealtime bolus insulin. Dose individually adjusted.
Study: NCT01350414

Intervention type: DEVICE
Intervention: Bronchial Thermoplasty with the Alair System
Description: Bronchial Thermoplasty with the Alair System
Study: NCT03053544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants will self-administer 500mg metformin twice daily by mouth: 1) beginning 1-2 weeks prior to standard of care CRT, 2) during standard of care CRT and 3) until 30 days after the end of standard of care CRT.
Study: NCT01177592

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VerifyNow, Verigene
Description: Subjects on chronic clopidogrel will be guided by VerifyNow P2Y12 assay, whereas clopidogrel naïve subjects will be guided by Verigene CYP2C19 genotyping assay. Patients on clopidogrel maintenance and/or in the control group will also be genotyped; conversely, clopidogrel naïve subjects will have VerifyNow testing prior to discharge for additional study analysis. Patients in the guided therapy group that have a measurement of ≥ 230 PRU will be reloaded with 60mg prasugrel and receive standard maintenance dosing. Similarly, clopidogrel naïve subjects that are considered CYP2C19\*2 carriers will also be reloaded with 60mg prasugrel and receive standard maintenance dosing (see flow schematic).
Study: NCT03662490

Intervention type: DEVICE
Intervention: High resolution oesophageal manometry
Description: High resolution oesophageal manometry (HRM) is the gold standard for the diagnosis of oesophageal motility disorder.
Study: NCT04343261

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma
Description: treatment with 2 Units of convalescent plasma
Study: NCT00826215

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: Nine sections of 45 minutes electroacupuncture treatment in three weeks

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham laser acupuncture
Description: Sham laser acupuncture
Study: NCT02460302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone
Description: Micronized vaginal progesterone 100mg inserted vaginally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo suppository inserted vaginally
Study: NCT04446520

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autogenic drainage
Description: breathing control using expiratory airflow to mobilize secretions from smaller to larger airways. Secretions are cleared independently by adjusting the depth and speed of respiration in a sequence of controlled breathing techniques during exhalation in addition to traditional physiotherapy (deep breathing exercise, diaphragmatic breathing and splinted coughing)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: autogenic drainage
Description: breathing control using expiratory airflow to mobilize secretions from smaller to larger airways. Secretions are cleared independently by adjusting the depth and speed of respiration in a sequence of controlled breathing techniques during exhalation in addition to traditional physiotherapy (deep breathing exercise, diaphragmatic breathing and splinted coughing)
Study: NCT03763214

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stenting with PTFE-coated stent (HILZO)
Description: Placing a metal stent in the biliary tract by duodenoscopy
Study: NCT01836029

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT03763214

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stenting with PTFE-coated stent (HILZO)
Description: Placing a metal stent in the biliary tract by duodenoscopy
Study: NCT03247530

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administered once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100mg SPN-812
Description: 100mg SPN-812 was administered once daily and compared to placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200mg SPN-812
Description: 200mg SPN-812 was administered once daily and compared to placebo
Study: NCT03729505

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pyloric injection of magnesium sulfate and lidocaine mixture
Description: 100 mg / 2 ml of magnesium sulphate (Magnesium Sulfate®) is mixed with 5 ml of 2% lidocaine and injected in the pylorus

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pyloric injection of saline
Description: 5 ml of normal saline is injected in the pylorus
Study: NCT03088982

Intervention type: OTHER
Intervention: Questionnaire
Description: FPs who had agreed to participate worked according to the following plan: first, the multimorbid patient was asked to give his/her consent to participate in the study once the terms had been explained to him/her. After that, FPs completed a questionnaire about their patient.~The purpose of this questionnaire was to explore potential decompensation risk factors within the themes and subthemes of multimorbidity.
Study: NCT00494078

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Real-time glucose monitoring system (Guardian, Medtronic)
Description: Patients randomised to the intervention arm are treated with intensive insulin therapy guided by the real time glucose monitoring system.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intensive insulin therapy
Description: intensive insulin therapy according to an algorithm
Study: NCT03571152

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational videos
Description: The level of practice and knowledge of the caregiver will be evaluated according to the video(s) corresponding to the session. Patient participation is expected for the evaluation of the caregiver's level of practice. After thirty minutes of use of the video, the level of practice and knowledge of the caregiver will be evaluated again for the same video. In each session this methodology will continue until the eighth video. At the end of all the videos, the level of satisfaction of the caregivers in relation to the videos will be evaluated.
Study: NCT03762421

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psycho-social skills development workshops based on PM plus
Description: 5 weekly, psycho-social skills development workshops will be conducted for newly inducted civil servants in groups, based on the problem management plus intervention. These workshops will be integrated into routine induction sessions of trainee civil servants. Workshop 1 orients participants to the intervention with motivational interviewing techniques to improve engagement, teaches the difference between technical and adaptive challenges, and trains participants in a basic stress management strategy. Workshop 2 addresses a participant-selected problem using problem-solving techniques and introduces behavioral activation. Workshops 3 and 4 support participants' continued application of problem solving, behavioral activation, and stress management and introduce strategies to strengthen social support networks whenever required. In Workshop 5, education about retaining intervention gains are provided and all learned strategies are reviewed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine training induction sessions
Description: The control group will receive 5 routine training induction sessions. These orientation sessions include lectures introduction to governance, public sector management, basic information technology, economics and public finance and official rules of procedure of the government of Pakistan. These lectures are held in a friendly and supportive environment.
Study: NCT03817177

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: high flow nasal cannula oxygenation
Description: high flow nasal cannula application in PACU

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: nasal prong
Description: conventional nasal prong application in PACU
Study: NCT03679936

Intervention type: DIAGNOSTIC_TEST
Intervention: PET/CT dynamic scan
Description: This study is designed to evaluate the patients who are first diagnosed with non-small cell lung cancer (NSCLC)，for 18 F-FDG PET/CT dynamic scanning and primary tumors and/or metastases in biopsy, than find the inner link of the tumor imaging findings, genomics and histopathologic characteristics, discuss diagnostic value of 18 F-FDG PET/CT dynamic imaging in metastatic non-small cell lung cancer (NSCLC). At the same time, evaluating the ability of 18 F-FDG PET/CT dynamic imaging to differentiating multiple primary lung cancer from intrapulmonary metastases.

Intervention type: DIAGNOSTIC_TEST
Intervention: PET/CT dynamic scan
Description: This study is designed to evaluate the patients who are first diagnosed with non-small cell lung cancer (NSCLC)，for 18 F-FDG PET/CT dynamic scanning and primary tumors and/or metastases in biopsy, than find the inner link of the tumor imaging findings, genomics and histopathologic characteristics, discuss diagnostic value of 18 F-FDG PET/CT dynamic imaging in metastatic non-small cell lung cancer (NSCLC). At the same time, evaluating the ability of 18 F-FDG PET/CT dynamic imaging to differentiating multiple primary lung cancer from intrapulmonary metastases.

Intervention type: DIAGNOSTIC_TEST
Intervention: PET/CT dynamic scan
Description: This study is designed to evaluate the patients who are first diagnosed with non-small cell lung cancer (NSCLC)，for 18 F-FDG PET/CT dynamic scanning and primary tumors and/or metastases in biopsy, than find the inner link of the tumor imaging findings, genomics and histopathologic characteristics, discuss diagnostic value of 18 F-FDG PET/CT dynamic imaging in metastatic non-small cell lung cancer (NSCLC). At the same time, evaluating the ability of 18 F-FDG PET/CT dynamic imaging to differentiating multiple primary lung cancer from intrapulmonary metastases.

Intervention type: DIAGNOSTIC_TEST
Intervention: PET/CT dynamic scan
Description: This study is designed to evaluate the patients who are first diagnosed with non-small cell lung cancer (NSCLC)，for 18 F-FDG PET/CT dynamic scanning and primary tumors and/or metastases in biopsy, than find the inner link of the tumor imaging findings, genomics and histopathologic characteristics, discuss diagnostic value of 18 F-FDG PET/CT dynamic imaging in metastatic non-small cell lung cancer (NSCLC). At the same time, evaluating the ability of 18 F-FDG PET/CT dynamic imaging to differentiating multiple primary lung cancer from intrapulmonary metastases.
Study: NCT01828957

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumostem®

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Study: NCT04000490

Intervention type: OTHER
Intervention: SCARE Score
Description: Predictive Score of acute coronary syndrome during the medical assessment of chest pain
Study: NCT02585960

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEGylated Recombinant Factor VIII
Description: Pharmacokinetic (PK) evaluation
Study: NCT00747708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating factor
Description: 5 days subcutaneous injection
Study: NCT02585960

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEGylated Recombinant Factor VIII
Description: Standard treatment

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEGylated Recombinant Factor VIII
Description: Intensified treatment
Study: NCT02683161

Intervention type: DRUG
Group type: OTHER
Intervention: Varenicline
Description: Varenicline will be administered as clinically indicated and will begin approximately 4-6 weeks prior to surgery. All participants will receive a 1-week dose induction period before transitioning to a full maintenance dose.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Contingency Management
Description: Contingency Management payments will begin on the target quit date (week 2) and will be in place for 5 weeks or until surgery (whichever is sooner). Participants will receive monetary incentives for biochemical evidence of smoking abstinence.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral Counseling
Description: All participants will complete a 3-session behavioral counseling intervention with a trained member of our study staff during 3 of the pre-surgical study visits. This brief counseling intervention provides participants with information about the experience of quitting smoking, including a benefits/disadvantage analysis, functional analysis of craving/risk periods, and skills-building exercises to prevent lapse and relapse.
Study: NCT02548650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorapaxar
Description: Triple therapy with DAPT plus vorapaxar (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vorapaxar
Description: Triple therapy with DAPT plus vorapaxar (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Triple therapy with DAPT plus vorapaxar (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Triple therapy with DAPT plus vorapaxar (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Triple therapy with DAPT plus vorapaxar(vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Triple therapy with DAPT plus vorapaxar(vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days
Study: NCT03149445

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Study medication will be administered for 91 days.
Study: NCT00486200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2151
Description: Oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2151
Description: Oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2151
Description: Oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2151
Description: Oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valacyclovir
Description: Oral administration of active comparator.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of placebo.
Study: NCT03230097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: 50 milligrams BI 409306, as a film-coated tablet, orally twice a day at approximately the same time every day in the morning and in the evening (approximately 12 hours apart) with or without food for 52 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo matching 50 milligrams BI 409306, as a film-coated tablet, orally twice a day at approximately the same time every day in the morning and in the evening (approximately 12 hours apart) with or without food for 52 weeks.
Study: NCT00187369

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Method of Delivery
Description: CS or VB

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Method of Delivery
Description: CS or VB
Study: NCT01506128

Intervention type: OTHER
Intervention: Collecting a Pad used at the first menstrual period after enrollment
Description: Collecting a Pad used at the first menstrual period after enrollment
Study: NCT00484874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I-131 Tositumomab therapeutic regimen
Description: Tositumomab and I-131 tositumomab are given intravenously. A test dose is given followed by a larger treatment dose.